No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 204-209

  Mathieu, Sylvain ^a   Pereira, Bruno ^a,b   Couderc, Marion ^a   Rabois, Emilie ^a   Dubost, Jean Jacques ^a   Soubrier, Martin ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Ankylosing spondylitis; Arterial stiffness; TNF inhibitors

Indexed keywords

ADALIMUMAB; CELECOXIB; DICLOFENAC; ETANERCEPT; FLURBIPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; MELOXICAM; PIROXICAM; PREDNISONE; TENOXICAM;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PULSE WAVE; SMOKING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84871155352     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes272     Document Type: Article

References (41)

1. Lautermann D, Braun J. Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol 2002;20(6 Suppl. 28): S11-5.
2. Vinsonneau U, Brondex A, Mansourati J et al. Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine 2008;75:18-21.
3. Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977;11:572-6.
4. Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 1980;23:57-61.
5. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with X-rays. BMJ 1982;13:449-60.
6. Hollan I, Saatvedt K, Almdahl SM et al. Spondyloarthritis: a strong predictor of early coronary artery bypass grafting. Scand J Rheumatol 2008;37:18-22.
7. Peters MJ, Visman I, Nielen MM et al. Ankylosing spondylitis; a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
8. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis. A systematic review and metaanalysis. Arthritis Care Res 2011; 63:557-63.
9. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009; 88:358-65.
10. Sattar N, McCarrey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63.
11. Divecha H, Sattar N, Rumley A et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 2005;109:171-6.
12. Papadakis JA, Sidiropoulos PI, Karvounaris SA et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009;27:292-8.
13. van Halm VP, van Denderen JC, Peters MJ et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1473-7.
14. van Eijk IC, de Vries MK, Levels JH et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60:1324-30.
15. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905-12.
16. Barnabe CCM, Martin BJ, Ghali WA. Effect of anti-tumor necrosis factor alpha therapy on cardiovascular events in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Rheum 2010;62:S128.
17. Sattar N, Crompton P, Cherry L et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9.
18. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-6.
19. Mathieu S, Joly H, Baron G et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47:1203-7.
20. McQueen MJ, Hawken S, Wang X et al. INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33.
21. van Eijk IC, Peters MJ, Serné EH et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009;68:362-6.
22. Syngle A, Vohra K, Sharma A et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010;29:763-70.
23. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
25. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
26. Szabo SM, Levy AR, Rao SR et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
27. Peters MJ, van Eijk IC, Smulders YM et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161-6.
28. Bodnar N, Kerekes G, Seres I et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011;38:723-9.
29. Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 2010;30:1441-6.
30. Capkin E, Kiris A, Karkucak M et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:378-82.
31. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
32. Roifman I, Beck PL, Anderson TJ et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174-82.
33. Kang JH, Chen YH, Lin HC. Comomrbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010;69: 1165-8.
34. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91-8.
35. Peterson K, McDonagh M, Thakurta S et al. Drug class review: nonsteroidal antiinflammatory drugs (NSAIDs): final update 4 report. Drug Class reviews. Oregon Health & Science University Nov 2010.
36. Pieringer H, Stuby U, Pohanka E et al. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010; 29:723-7.
37. Angel K, Provan SA, Gulseth HL et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010;55:33-8.
38. McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 2009;27:S124-6.
39. Daien CI, Duny Y, Barnetche T et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012;71:862-8.
40. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68: 460-9.
41. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms on inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.